Optex Systems Holdings arrives at its May 14 fiscal Q2 print having just surged 13% in a single session — yet the CEO has been a consistent seller throughout the past year.
The price action heading into the report is striking. Shares jumped 12.8% on May 12 to $11.75, bringing the one-week gain to 7.7%. That follows a March-to-April selloff that dragged OPXS down more than 26% year-to-date before the recent rebound. The stock also moved sharply after its most recent earnings announcement on May 11 — up 15.2% in one session — suggesting the market is sensitive to any guidance-level signal from this small defense name.
Against that backdrop, the insider picture adds a layer of caution. Chairman and CEO Danny Schoening sold over 80,000 shares across seven transactions in early January 2026, raising roughly $1.1 million as the stock traded in the $13-$14 range — well above current levels. A further sale by a President-level insider followed in March. Schoening remains the largest individual holder at 11.5% of shares, but the direction of travel has been consistently outward. Institutional holders tell a slightly more constructive story: Wasatch Advisors added 132,405 shares through Q1, and Vanguard lifted its position by 41,419 shares — two funds moving against the grain of insider selling.
Short interest is not the story here. At just 0.72% of the free float, short positioning is minimal and has actually declined about 17% over the past month. Borrow costs are negligible at 0.55% and availability is loose. The ORTEX short score of 28 sits near the bottom third of the universe — there is no meaningful short-side pressure anywhere in the lending market.
The fundamental setup is what the print will test. Consensus estimates point to roughly $47.5 million in revenue and $6.1 million in EBITDA for the period, with normalized net income near $4.5 million and EPS around $0.64. The company's enterprise value of ~$76 million implies a modest multiple — but with a market cap of only ~$70 million, the print needs to confirm that margins are holding as the backlog scales. The RSI at 38 — technically oversold on a medium-term basis — and a YTD loss of 26% mean the stock still carries a gap to recover, even after its recent bounce. The earnings report is therefore less about the revenue line and more about whether Optex can show margin discipline that justifies a re-rating above the $13-$14 range where its own CEO chose to sell.
See the live data behind this article on ORTEX.
Open OPXS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
